As part of our series focussing on available medicines in Australia, we have added a product review of use of Ozanimod for the treatment of moderate to severe ulcerative colitis.
This review discusses Sphingosine-1-phosphate modulators, indications and dosage, contraindications and a series of clinical studies featuring Ozanimod use. It also provides commentary and recommendations from Associate Professor Emily Wright, a Gastroenterologist and acting head of Inflammatory Bowel Diseases at St Vincent’s Hospital Melbourne.
Please login below to download this issue (PDF)